Accessibility Menu
Vectus Biosystems logo

Vectus Biosystems(ASX) VBS

Market CapA$9.90MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2016)-90%
5 Year-88%
1 Year+167%
1 Month+19%
A$0.16
+0.00%
+0.00Today
Vectus Biosystems last closing stock price
MetricPriceDate
Last closeAUD 0.162026-08-06
Vectus Biosystems stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week+23.08%AUD 0.132026-07-30
1 month+18.52%AUD 0.142026-07-07
3 month+28%AUD 0.132026-05-08
Year to date-11.11%AUD 0.182025-12-31
1 year+166.67%AUD 0.062025-08-01
3 year-64.44%AUD 0.452023-08-07
5 year-87.6%AUD 1.292021-08-04
Since inception-89.68%AUD 1.552016-02-23

Vectus Biosystems Financials at a Glance

Market Cap

A$9.90MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

A$968.68K

Net Income (TTM)

-A$3.67M

EPS (TTM)

-A$0.03

P/E Ratio

-6.06

Dividend

A$0.00

Beta (Volatility)

-0.03 (Low)

Price

A$0.16

Volume

10,000

Open

A$0.16

Previous Close

A$0.16

Daily Range

A$0.16 - A$0.16

52-Week Range

A$0.05 - A$0.46

Estimated Earnings Date

Feb 19, 2026

VBS News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Vectus Biosystems

Vectus Biosystems Limited is an Australian biotechnology firm focused on developing innovative therapies for fibrotic conditions and hypertension. The company’s pharmaceutical pipeline targets critical ailments affecting vital organs, including the heart, kidneys, liver, and lungs.

Products and Services
  • VB0004: An experimental drug aimed at combating tissue degradation from fibrosis
  • AccuCal: Software designed for precise DNA and RNA quantification
  • RealCount: A tool to enhance laboratory efficiency in quantification processes
Growth Outlook
  • Ongoing clinical trials for VB0004 show promise in treating fibrotic diseases
  • Expansion into hepatic fibrotic disease treatments is underway
  • Strategic partnerships may enhance research capabilities and market reach
Financial Highlights
  • Recent quarterly revenue of AUD 0 indicates a focus on R&D investments
  • Trailing twelve months (TTM) net income shows a loss of AUD 1.17 million
  • Cash reserves increased to AUD 330,496, supporting ongoing operations
Vectus Biosystems Limited is positioned in a niche market with significant growth potential. The company’s focus on developing therapies for fibrotic conditions and hypertension addresses critical health issues, which may attract interest from investors looking for opportunities in the biotechnology sector. The ongoing development of VB0004 and other therapeutic solutions highlights the company's commitment to innovation. Despite recent financial challenges, the increase in cash reserves indicates a strategic approach to sustaining operations and funding future research initiatives.
AI Generated • Jul 23, 2026

Industry

Biotechnology

Sector

Health Care

CEO

Karen Duggan, MD

Website

www.vectusbiosystems.com.au

Headquarters

Rosebery, NSW 2018, AU

VBS Financials

Key Financial Metrics (TTM)

Gross Margin

98.13%

Operating Margin

-1646.01%

Net Income Margin

-1667.94%

Return on Equity

265.12%

Return on Capital

N/A

Return on Assets

-305.21%

Earnings Yield

-16.50%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

A$9.90MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

61.87M

Volume

10.00K

Avg. Volume

44.70K

Financials (TTM)

Gross Profit

A$967.10K

Operating Income

-A$3.53M

EBITDA

-A$3.53M

Operating Cash Flow

-A$2.27M

Capital Expenditure

A$27.01K

Free Cash Flow

-A$2.24M

Cash & ST Invst.

A$330.50K

Total Debt

A$467.10K

Vectus Biosystems Performance Analysis

Vectus Biosystems annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-06-30AUD 0N/A
20232023-06-30AUD 0N/A
20242024-06-30AUD 0N/A
20252025-06-30AUD 0N/A
Vectus Biosystems sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q42024-06-30-24.3%
Q22024-12-31-19.7%
Q42025-06-30-78.5%
Q22025-12-31-100.0%
Vectus Biosystems annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-06-30AUD -0.12N/A
20232023-06-30AUD -0.07-40.0%
20242024-06-30AUD -0.04-38.7%
20252025-06-30AUD -0.03-24.1%
Vectus Biosystems sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q42024-06-301.8%
Q22024-12-315.0%
Q42025-06-3038.6%
Q22025-12-31-7.9%

Revenue Growth Rate

Annual and quarterly growth comparison

Currently no data to display.

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q2 2026YOY CHG

Revenue

A$0.00

-100.0%

Gross Profit

-A$1.58K

-100.3%

Gross Margin

0.00%

N/A

Market Cap

A$9.90MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

A$1.98M

N/A

Employees

5

N/A

Net Income

-A$731.69K

+37.9%

EBITDA

-A$714.05K

+37.7%

Quarterly Fundamentals

Name
Q2 2026YOY CHG

Total Cash

A$330.50K

-84.2%

Total Debt

A$467.10K

+1603.0%

Accounts Receivable

A$14.64K

-98.2%

Inventory

A$0.00

-100.0%

Long Term Debt

A$467.10K

+1603.0%

Short Term Debt

A$0.00

N/A

Return on Assets

-3.05%

N/A

Return on Invested Capital

4.15%

N/A

Free Cash Flow

-A$170.49K

+80.2%

Operating Cash Flow

-A$170.49K

+77.8%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
IXC.AXInvex Therapeutics Ltd
A$0.12+0.00%
BGT.AXBio-Gene Technology Limited
A$0.02+0.00%
ACR.AXAcrux Limited
A$0.01-0.00%
HIQ.AXHITIQ Limited
A$0.01+0.00%

Trending Stocks

Symbol / CompanyPricePrice Chg
ONDSOndas
$8.91-0.09%
SMCISuper Micro Computer
$39.16+0.04%
SPCXSpace Exploration Technologies
$141.29-0.03%
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x ETF
$8.64+0.07%

Questions About VBS

What is the current price of Vectus Biosystems?

Vectus Biosystems is trading at A$0.16 per share.

What is the 52-week range for Vectus Biosystems?

Over the past 52 weeks, Vectus Biosystems has traded between A$0.05 and A$0.46.

How much debt does Vectus Biosystems have?

As of the most recent reporting period, Vectus Biosystems reported total debt of A$200.00K.

How much cash does Vectus Biosystems have on hand?

Vectus Biosystems reported A$250.99K in cash and cash equivalents in its most recent financial results.

What is Vectus Biosystems’s dividend yield?

Vectus Biosystems does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services